Through contemporary literature, the optimal strategy to manage coronary chronic total occlusions (CTOs) remains under debate.
Introduction
Percutaneous coronary intervention (PCI) for coronary chronic total occlusions (CTOs) remains one of the major challenges in interventional cardiology.
1,2 A CTO is a frequent condition encountered in catheterization laboratory and its prevalence in patients undergoing coronary angiography was reported to range from 12 to 20%. 3, 4 Although several observational studies have shown that successful PCI was associated with an improvement of symptoms and quality of life, a reduction in the need for coronary artery bypass grafting (CABG) surgery and an increase in long-term survival, 5 -8 only a minority of CTO patients are treated percutaneously. 9 This might be explained by several reasons: the complexity of CTO procedures, which seek for specific equipments and dedicated operators in order to achieve a similar rate of success than non-CTO lesions; the fact that CTO PCIs are time-consuming procedures associated with elevated radiation exposure, increased amount of contrast load and higher risk of procedural complications; and the lack of prospective outcome data in respect to the adopted management strategy for CTO lesion [optimal medical therapy (MT), CABG, or PCI). The aim of the Italian Registry of Chronic Total Occlusions (IRCTO) was to provide detailed data on prevalence, characteristics, and outcome of CTO patients according to the adopted treatment strategy.
Methods

Study population
The IRCTO is a prospective real world all comers multicentre registry, enrolling patients showing at coronary angiography ≥1 CTO in a main coronary artery (vessel size ≥2.5 mm). A prior CABG procedure or a life expectancy ,1 year represented the exclusion criteria. The enrolment started on March 1st 2008 and continued up to 1 year, in 12 high-volume Italian centres, where a total of 15 619 patients underwent coronary angiography during the enrolment period. Figure 1 shows the flowchart of the study population.
At the enrolment, the participating physicians prospectively inserted all data into a webmaster database. Data collection included patients clinical [age, risk factors, peripheral artery disease, chronic obstructive pulmonary disease, left ventricular ejection fraction (LVEF), chronic renal failure (defined as creatinine clearance ,60 ml/min), clinical presentation, viability related to CTO vessel and prescribed medication] and angiographic characteristics (CTO artery, presence of multi-vessel coronary disease, presence of blunt stump, severe calcification, bridge collaterals, and CTO length). In case of CTO PCI strategy, procedural data were also collected.
Patients' follow-up was performed either by a clinical visit or by a telephone interview. At follow-up, details regarding major adverse cardiac and cerebrovascular events (MACCE) occurrence, and rehospitalization for a cardiovascular reason were collected by the physicians through the revision of clinical source documentation. The study was carried out in accordance to the Helsinki declaration; the ethics committee approved the protocol and all patients provided written informed consent.
Definitions and end-points
Coronary CTO was defined as thrombolysis in myocardial infarction (TIMI) Grade 0 flow within the occluded segment with an occlusion duration .3 months. The occlusion duration was divided into three levels of certainty: (i) 'certain' (angiographically confirmed), in cases where a previous angiogram confirmed the presence of TIMI 0 flow .3 months prior to the index procedure; (ii) 'likely' (clinically confirmed), objective evidence of an acute myocardial infarction (AMI) in the territory of the occluded artery without other possible culprit arteries of .3 months before the current angiogram; (iii) 'undetermined', TIMI 0 flow and angiographic anatomy suggestive of long-standing occlusion with stable anginal symptoms unchanged in the last 3 months or evidence of silent ischaemia. 1, 9 All baseline and procedural cine coronary angiograms were analysed and reviewed in each centres by consensus of two expert operators; in case of disagreement, an additional evaluation by a third expert operator was performed. Severe calcifications were defined as multiple persistent opacifications of the coronary wall visible in more than one projection surrounding the complete lumen of the coronary artery at the site of the lesion. Severe tortuosity was defined as one or more bends of 908 or more, or three or more bends of 45 -908 proximal to the diseased segment.
A 2D echocardiogram was performed in all patients. In presence of normal wall motion or hypokinesia in the territory subtended by the CTO artery, no further viability testing was performed; while in patients with akinesia or dyskinesia in CTO territory, assessment of viability was performed by myocardial scintigraphy or myocardial resonance imaging. 10 Patients received medical anti-ischaemic therapy as established by practice standards: anti-ischaemic drug included b-blockers, calcium channels blockers, nitrates, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other antianginal drugs alone or in combination. Optimal MT was defined according to the appropriate use criteria, as the use of at least two or more antianginal classes of S.D. Tomasello et al.
therapies. 11 The MT was recorded at discharge after the index hospitalization.
The decision of the management strategy for each patient was left to the local heart team in the participating centre. Patients were categorized in PCI group, when the CTO lesion was attempted percutaneously regardless of the procedural success, while those in whom the CTO lesion was not attempted were categorized in MT group regardless of the management of other non-CTO lesions. In case of percutaneous treatment, the operators performed the procedures according to their understanding of each particular case needs. The choice of the appropriate CTO revascularization technique took into account the angiographic characteristics of the lesions and operator personal skills according to antegrade and retrograde techniques previously described. 12, 13 The sequence of use of these wiring techniques and the guidewire selection was completely left to operator's discretion. In patients with more than one CTO, only one CTO vessel was attempted (the choice of the target CTO vessel was left to operator's discretion) and no further CTO attempt was performed during the study period. A successful PCI was defined as a final residual stenosis ,30%, with a TIMI grade flow 3 after stent implantation. At the beginning of the procedure, patients received intravenous unfractionated heparin (80-100 IU/kg) to maintain an activated clotting time .300 s, and the activated clotting time was monitored every 30 min to determine if an additional bolus of unfractionated heparin was necessary. Glycoprotein IIb/IIIa inhibitors were administered after CTO recanalization at operator's discretion. The antiplatelet therapy after stent implantation was prescribed according to recognized standard of care.
14 In the majority of cases, a 300 or 600 mg loading dose of clopidogrel was administered prior to the procedure, and dual antiplatelet therapy with aspirin (≥75 mg daily) and clopidogrel (75 mg daily) was prescribed for 12 months after discharge. In case of surgical indication for myocardial revascularization, the patients were transferred to the referral cardio-surgical centre during the index hospitalization.
A 1-year follow-up period was obtained in all patients. Major adverse cardiac and cerebrovascular events were defined as a composite of cardiac death, stroke, and AMI. All deaths were considered of cardiac origin unless otherwise documented. Acute myocardial infarction was defined as creatine kinase (CK)-MB enzyme elevation .3 times the upper limit of the normal value, with or without the presence of new pathological Q waves, in 12-lead electrocardiogram (ECG). 15 In all patients, CK-MB were evaluated 6 h after the procedure and until normalization if the levels were abnormal. The incidence of re-hospitalization due to cardiac cause (new ischemic events, heart failure) during followup was also evaluated.
Statistical analysis
Continuous variables were presented as mean + standard deviations and were compared using one-way analysis of variance. Categorical variables were presented as counts and percentages and compared with the x 2 test when appropriate (expected frequency .5).Otherwise, the Fisher exact test was used. The predictors of the management strategy were identified using a logistic regression for each therapeutic alternative (optimal MT, CABG, and PCI). All clinical and angiographic characteristics were tested. All univariate variables with a P , 0.1 were included in a statistical model in order to detect the independent predictors using multivariate regression analysis with the Wald method. The same methodology was used to identify the predictors of 1-year MACCE occurrence.
To reduce the impact of treatment selection bias and potential confounding factors, we performed a rigorous adjustment for significant differences in baseline clinical characteristics of patients by propensity score matching (PSM). The propensity score is defined as the conditional probability of receiving treatment given a set of selected covariates. We used a stratification matching model: after dividing the population into 9 equal 10 points layers, we matched the MT-treated units to the PCI-treated units based on the closest propensity score within each layer. We started from a population of 1602 units (in PSM 175 CABG cases were excluded) and after PSM we obtained a population of 1238 units, equally divided between PCI group and MT group. We consider the following variables: age, sex, hypertension, dyslipidaemia, diabetes, smoking status, clinical presentation, chronic kidney disease, prior Italian Registry of Chronic Total Occlusions MI, prior PCI, and LVEF , 30%. Chi-square tests were re-run in the matched pairs to check whether differences between the two groups across the selected variables persisted after matching. Event-free survival during follow-up was evaluated according to the Kaplan -Meier method and survival among groups was compared using the log-rank test. All data were processed using the Statistical Package for Social Sciences, version 19 (SPSS, Chicago, IL, USA).
Results
Clinical and angiographic characteristics
At the end of the recruitment phase, a total of 1777 patients with 1968 CTOs were enrolled into the study, for an overall CTO prevalence of 13.3%. The occluded artery was more frequently the right coronary artery (49.7%) in comparison with left anterior descending (28.8%) and left circumflex (21.5%). The adopted therapeutic strategies were as follows: MT in 826 patients (46.5%), PCI in 776 patients (43.7%), and CABG in the remaining 175 patients (9.8%). Table 1 summarized the clinical characteristics of the study population according to the chosen therapeutic strategy. Patients managed with MT were older and showed a higher prevalence of chronic renal failure in comparison with patients treated percutaneously (both P , 0.001). In patients managed by MT or referred to CABG, a pathological Q wave was more frequently observed in electrocardiogram when compared with those who underwent PCI (MT 57.4%, CABG 53.7%, PCI 40.5%; P , 0.001 for both MT vs. PCI and CABG vs. PCI, respectively). Whereas in patients managed with PCI LVEF was more frequently preserved and viability more frequently demonstrated in comparison with those treated by MT or CABG. Importantly, an optimal MT was prescribed in the majority (98.2%) of MT patients group, while only 55% of PCI group patients were on optimal MT (P , 0.001). According to angiographic characteristics, CTO lesions managed by PCI showed more frequently a blunt stump and bridge collaterals in comparison with the two other groups (all P , 0.05) ( Table 2) .
Predictors of management strategy
Low LVEF (OR 2.74, 95% CI 1.32 -5.67; P ¼ 0.007), chronic renal failure (OR 3.38, 95% CI 1.27 -9.30, P , 0.001), the absence of myocardium viability in the CTO territory (OR 2.73, 95% CI 1.47 -5.08; P ¼ 0.001) were recognized as independent predictors of MT strategy.
Percutaneous coronary intervention treatment was predicted by the presence of viable myocardium (OR 1.48, 95% CI 1.20 -1.83; P , 0.001), bridge collateralization (OR 1.55, 95% CI 1.25 -1.91; P , 0.001), LAD as a culprit CTO artery (OR 1.53, 95% CI 1.22 -1.91; P , 0.001), the absence of chronic renal failure (OR 0.54, 95% CI 0.41-0.85; P ¼ 0.004), the absence of left ventricular function impairment (OR 0.59, 95% CI 0.40 -0.72; P , 0.001), and a younger age (OR 0.98, 95% CI 0.97-0.99; P , 0.001).
Finally, patients were more frequently referred to CABG in case of multi-vessel coronary disease (OR 2.18, 95% CI 1.45 -3.13; P , 0.001), in presence of more than one CTO lesion (OR 3.13, 95% CI 1.81 -5.41; P , 0.001), and in absence of myocardium viability in CTO territory (OR 1.87, 95% CI 1.32 -2.66; P , 0.001). Table 3 showed procedural details and peri-procedural complications of CTO patients managed percutaneously. The rate of angiographic success of CTO PCI was 75.4%. At 1-year follow-up, patients managed by MT and CABG experienced higher rate of cardiac death (4.7% and 6.3% vs. 1.4%; P , 0.001) and overall MACCE (8.2% and 6.9% vs. 2.6%; P , 0.001) in comparison with those treated by PCI independently of angiographic success. Patients referred to CABG had higher incidence of stroke than those managed by MT and PCI (5.1% vs. 0.7% and vs. 0.1%, respectively; all P , 0.001), while patients managed with MT showed higher rates of AMI and rehospitalization than those treated by PCI and CABG (3% vs. 1% vs. 0.6% and 3.9% vs. 1.9% vs. 2.9%, respectively; all P , 0.05) ( Table 4) .
Clinical outcome
Age (per 10-year increase) [odds ratio (OR) 1.60, 95% CI 1.29-1.98; P , 0.001), chronic renal failure (OR 3.22, 95% CI 2.0 -5.2; P , 0.001), MT or CABG strategies (OR 2.69, 95% CI 1.62 -4.47) were recognized as independent predictors of MACCE at 1-year follow-up ( Figure 2) .
Patients with successfully PCI for CTO showed a better 1-year outcome in comparison with other groups (Figure 3 ).
Outcome adjusted by propensity matched analysis
After propensity analysis execution, 539 could not be matched; thus, a total of 1238 patients was obtained (619 patients for each group). No differences were observed in clinical baseline characteristics (Supplementary material online, Table S1 ). The success rate in adjusted PCI group was 74%. Table 5 summarizes the 1-year clinical outcome after propensity score analysis. As compared with patients treated by PCI, those managed by MT experienced higher incidence of MACCE (7.6 vs. 1.7%; P , 0.001), death (4.4 vs. 1.5%; P ¼ 0.002), AMI (2.9 vs. 1.1%; P ¼ 0.03), and re-hospitalization (4.4 vs. 2.3%; P ¼ 0.04). Figure 4 shows the Kaplan -Maier survival curves free from MACCE and from death according to the adopted strategy (PCI vs. MT).
Discussion
The IRCTO study was performed to determine the prevalence, the clinical and angiographic characteristics, and the management of CTO patients. Moreover, our study shows how clinical outcome of this patients' subset might change according to the different therapeutic strategies adopted in a real world all comers population.
Prevalence and characteristics of patients affected by chronic total occlusion lesions
The real prevalence of CTO lesions in patients affected by coronary artery disease (CAD) is unknown due to the fact that a great proportion of these patients are asymptomatic and thus, not referred to cardiological evaluation. In a large registry enrolling 6581 consecutive patients undergoing coronary angiography, a CTO lesion was observed in more than half patients (52%) affected by significant CAD. 16 More recently, in a veteran population, Jeroudi et al. 17 confirmed that coronary CTOs are highly prevalent in CAD patients without prior CABG (31% of cases). Figure 3 Kaplan-Meier analysis of freedom from major adverse cardiac and cerebrovascular events in patients with successful percutaneous coronary intervention, failed percutaneous coronary intervention, patients managed by medical therapy and those referred to coronary artery bypass grafting, before propensity score adjustment. CABG, coronary artery bypass grafting; MACCE, major adverse cardiac and cerebrovascular adverse events; PCI, percutaneous coronary intervention.
Italian Registry of Chronic Total Occlusions
In the Canadian multicentre CTO registry, Fefer et al. 3 reported an overall CTO prevalence of 18.4% among 1697 patients undergoing non-emergent coronary artery angiography. The majority of CTO patients did not have signs of myocardial scar (Q waves at ECG) and showed a well-preserved myocardial function. 3 In our study, the prevalence of CTOs was 13.3%, and the most common CTO artery was the RCA in accordance to previous reports. 3,16 -18 Prior myocardial infarction was diagnosed in 43% of cases; an abnormal ECG related to CTO lesion was observed in almost 50% of cases while, viability in the territory subtending the CTO was shown in 75% of patients. Differently from Canadian multicentre CTO registry, where only 13% reported no or only mild symptoms (Canadian Cardiovascular Society class 0/1), 3 almost a quarter of our patients were completely asymptomatic and in 16.7% of cases CTO was revealed in the setting of AMI related to a non-CTO vessel. Notably, more than two-thirds of our population had a multivessel coronary disease and multiple CTO lesions affected .10% of patients. These latter findings were similar to those reported in the European Registry of CTOs (ERCTO registry), 19 confirming that CTO lesions are associated with an extensive atherosclerosis burden. Furthermore, Jeroudi et al. 17 found that CTO patients were more likely to have both cardiac and non-cardiac comorbidities (particularly diabetes and peripheral artery disease) than those with non-occlusive coronary stenoses.
Management strategy of chronic total occlusions patients
Christofferson et al. 16 reported that only a minority of CTO patients underwent percutaneous revascularization (11%). Indeed, the majority of them were referred to surgical revascularization (40%) or managed conservatively by MT (49%), differently from patients with non-CTO lesions. 16 Similarly, in the Canadian CTO registry, MT was the preferred strategy for treating CTOs (approximately two-thirds of patients), followed by CABG ( 25%); whereas, PCI was attempted in less than 10% of cases. 3 Conversely, in our cohort 43.7% of CTO patients were treated by PCI, while the remaining patients were left on MT or referred to surgery (46.5 and 9.8%, respectively). Our data are in accordance to those of Jeroudi and colleagues, 17 who reported the use of PCI in 50% of CTOs patients.
On the other hand, patients enrolled in our study were relatively older than those of Canadian Registry, with lower prevalence of diabetes and higher rate of prior PCI. These reasons might explain in part the lower rate of CABG indication in IRCTO when compared with the Canadian registry.
Although the majority of interventionalists in the past used to avoid CTO PCI attempts, being these latter costly, associated with high radiation exposure and high probability of procedural failure, the recent progress in equipment and techniques 12, 13, 20 leading to the increase of success rate, and the reduction of peri-procedural complications have encouraged the widespread of percutaneous approach in treating CTO lesions. Several factors might influence the decision-making process in the setting of a CTO. Our findings are similar to those reported in the Canadian multicentre CTO registry, 3 where low-risk patients were the most suitable candidates for CTO PCI. On the other hand, although patients with low LVEF could take benefit from a functional complete revascularization, their fragility may suggest managing them conservatively by MT, especially in absence of symptoms or viability. 21 Furthermore, operators could be more reluctant to perform cumbersome procedures in elderly patients with impaired renal function to avoid complications, particularly contrast-induced nephropathy.
Otherwise, there are two clinical scenarios involving CTO lesions: single-and multi-vessel CAD. In case of isolated CTO, symptoms are generally atypical, and angina could be less prominent than shortness of breath. 22 Furthermore, the potential benefit of a successful PCI could be diminished by the loss of the protective effect of collaterals. Hence, CTO PCI might be deferred until intensive MT is proven to be inadequate to satisfactorily improve symptoms. Differently, multi-vessel coronary disease was found to be a predictor for referring CTO patients to CABG, as recommended by the appropriate criteria of use for myocardial revascularization.
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Outcome according to the management strategy
According to the COURAGE trial, as an initial management strategy in patients with stable CAD, PCI did not reduce the long-term risk of death, MI, or other major cardiovascular events when compared with only optimal MT. 23 However, this latter study had likely considered CTOs to be technically unsuitable lesions for PCI, thus CTO patients have not been probably included. Conversely, our results supported that PCI might improve the cardiovascular outcome in comparison with MT in the setting of CTO lesions. Notably, at 1 year follow-up, the rate of cardiac death, MI, and overall MACCE observed in our MT group was relatively higher than those of COURAGE MT cohort. The current European guidelines assigned a class IA for PCI in the presence of stenotic lesions, while they classified the indication for CTO PCI as IIa only. 24 Thus, one question arises in light of these findings, is the presence of CTO rather not as harmless as it is assumed in current guidelines? Data obtained from UK Central Cardiac Audit Database revealed that successful CTO PCI was associated with improved long-term survival independently from the treated CTO vessel [hazard ratio (HR) 0.72; 95% CI 0.62 -0.83; P , 0.001] and that the greatest improvement was obtained in case of complete revascularization (0.70; 95% CI 0.56-0.82; P ¼ 0.002). 25 Several reasons may explain such a finding including the potential complications related to a failed CTO PCI, and the worse outcome associated with an incomplete revascularization. 26 Moreover, PCI failure can be the marker of disease burden and other comorbidities limiting the vigour of CTO PCI attempt. Thus, the role of revascularization for CTO lesion remains debatable. A meta-analysis by Joyal et al. 27 compared the outcomes of patients with successful vs. 31 After PSM, the incidence of cardiac death (HR: 0.27; 95% CI: 0.09 -0.80; P ¼ 0.02) and MACE (HR: 0.44; 95% CI: 0.23 -0.82; P ¼ 0.01) were still significantly lower in revascularization group than in MT group. 31 The lack of available randomized trials that would address the question of whether successful CTO PCI improved survival in comparison with MT remains one of the main arguments against the expansion of CTO PCI indication. In this respect, the Drug-Eluting Stent Implantation vs. Optimal Medical Treatment in Patients with Chronic Total Occlusion trial (NCT01078051) is currently randomizing patients with CTOs and stable angina to PCI vs. MT to assess the impact of the intervention on cardiac mortality and MI during a follow-up of 5 years.
Despite its non-randomized nature, the current IRCTO trial contributes to improve the evidence of the long-term benefit of CTO PCI in a real world population when compared with MT and CABG.
Study limitations
This study presents some limitations. First of all, although an appropriate propensity score-matched analysis was performed, the nonrandomized nature of the study cannot completely exclude all selection bias. Third, the small number of patients referred to CABG could also introduce some selection bias in the data evaluation. Fourth, viability assessment was performed only in patients with akinesia or dyskinesia in myocardial region subtended CTO artery. Fifth, Syntax score was not assessed and the study does not take into account the status of functional complete revascularization after revascularization either percutaneously or surgically. Sixth, MACCE definition did not include target vessel failure or revascularization. Sixth, we did not address an assessment of quality of life before and after each management strategy. Finally, data regarding PCI of non-CTO lesions in MT group and the rate of CTO grafted in patients undergoing CABG were not assessed as these topics were beyond the scope of the study. Nevertheless, our study represents the largest multicentre comparison of treatment strategies in patients affected by coronary CTOs.
Conclusions
The present study provides information regarding CTO prevalence in a contemporary catheterization laboratory practice with detailed characterization of clinical and angiographic parameters and management trends. More importantly, these data highlight at 1-year follow-up, a significant reduction in MACCE and cardiovascular death for CTO patients treated by PCI when compared with those managed by MT or referred to CABG.
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